SAN FRANCISCO and BOSTON, Jan. 09, 2026 (GLOBE NEWSWIRE) — MapLight Therapeutics, Inc. (MapLight) (Nasdaq: MPLT) today announced an update to the expected timing of topline results for its ongoing Phase 2 ZEPHYR and IRIS clinical studies, which are progressing ahead of schedule. The company’s Phase 2 ZEPHYR trial evaluating ML-007C-MA for the treatment of schizophrenia continues to enroll robustly, and topline results are now expected in the third quarter of 2026. The ZEPHYR study is a randomized, double-blind, placebo-controlled trial that is expected to enroll 300 hospitalized adult participants with schizophrenia experiencing acute exacerbation of psychosis. “The accelerated enrollment pace in the ZEPHYR trial allows us to narrow our timing guidance to the third quarter of 2026,” said Chris Kroeger, co-Founder and Chief Executive...

SAN DIEGO, Jan. 09, 2026 (GLOBE NEWSWIRE) — iBio, Inc. (NASDAQ:IBIO), an AI-driven innovator of precision antibody therapies, today announced that it has entered into a securities purchase agreement with existing healthcare-focused, high-quality institutional investors for a private placement (“PIPE”) financing that is expected to result in gross proceeds of approximately $26 million to the Company before placement agent fees and offering expenses. The offering is expected to close on or about January 13, 2026, subject to customary closing conditions. The financing was led by Frazier Life Sciences and included participation from other existing investors. iBio intends to use the net proceeds received from the offering to advance its preclinical cardiometabolic programs, including IBIO-610, IBIO-600, and the myostatin...

NOT FOR DISTRIBUTION TO UNITED STATES NEWS WIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES VANCOUVER, British Columbia, Jan. 09, 2026 (GLOBE NEWSWIRE) — VR Resources Limited (“VR” or the “Company”, TSXV: VRR) announces that due to significant investor demand, it has increased the size of its previously announced brokered private placement offering (the “Offering”). Pursuant to the upsize, the Company will issue up to 9,375,000 units (the “Units) for aggregate gross proceeds of $1,500,000. Centurion One Capital Corp. (the “Lead Agent”) is acting as lead agent and sole bookrunner. In addition, the Company has agreed to grant to the Lead Agent an option exercisable, in whole or in part, at the sole discretion of the Lead Agent, to sell up to $500,000 in additional Units pursuant to the Offering. As previously disclosed, each...

SHENZHEN, China, Jan. 09, 2026 (GLOBE NEWSWIRE) — Aurora Mobile Limited (NASDAQ: JG) (“Aurora Mobile” or the “Company”), a leading provider of customer engagement and marketing technology services in China, today announced that it has entered into a strategic partnership with Xiaoe Inc. (“Xiaoe”) to integrate its intelligent push notification solution, JPush, into Xiaoe’s flagship private domain SaaS platform. When operating private domains, a platform’s value lies not only in providing operational tools but also in enabling continuous and effective interactions between merchants and users. Missed service alerts and delayed notification can limit service coverage and weaken user engagement. Xiaoe acts as a bridge between brands and users, helping countless merchants build their digital presence. Recognizing the critical role that...

Announces receipt of FDA letter stating it has identified deficiencies that preclude labeling discussions for Anaphylm at this time  Receives confirmation from FDA that Agency’s review of Anaphylm NDA application is ongoing and no final FDA decision has been made Progresses global regulatory expansion activities in Canada, Europe, and the United Kingdom for Anaphylm Unaudited cash and cash equivalents of approximately $120 million as of December 31, 2025WARREN, N.J., Jan. 09, 2026 (GLOBE NEWSWIRE) — Aquestive Therapeutics, Inc. (NASDAQ: AQST) (“Aquestive” or the “Company”), a pharmaceutical company advancing medicines to bring meaningful improvement to patients’ lives through innovative science and delivery technologies, today provided an update on the regulatory approval of Anaphylm™ and...

DUBLIN and BRIDGEWATER, N.J., Jan. 09, 2026 (GLOBE NEWSWIRE) — Amarin Corporation plc (NASDAQ: AMRN), a company advancing the science of cardiovascular therapeutics worldwide, today commented on recent innovations in therapies for patients with elevated triglycerides (TG) and shared its perspective on how these developments stand to shape patient access and treatment strategies. Specifically, new therapies for these patients are likely to expand the use of existing, proven options over time, including Amarin’s VASCEPA®/VAZKEPA® (icosapent ethyl), an effective, safe, oral therapy that has been prescribed more than 25 million times to patients globally. In addition, through its approved indication for severe hypertriglyceridemia (sHTG), which is defined as TG ≥500 mg/dL, as well as strong clinical evidence, affordability, and broad...

LOS ANGELES, Jan. 09, 2026 (GLOBE NEWSWIRE) — RadNet, Inc. (NASDAQ: RDNT), a national leader in providing high-quality, cost-effective diagnostic imaging services through a network of fully-owned and operated outpatient imaging centers, today announced that Dr. Howard Berger, President and Chief Executive Officer, Mark Stolper, Executive Vice President and Chief Financial Officer, Dr. Gregory Sorensen, Executive Vice President and Chief Strategy Officer and Kees Wesdorp, President & CEO of RadNet Digital Health will be presenting at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco, CA on Wednesday, January 14, 2026 at 10:30 a.m. PST. A live webcast of RadNet’s presentation can be accessed through the following link, https://jpmorgan.metameetings.net/events/healthcare26/sessions/317344-radnet-inc/webcast?gpu_only=true&kiosk=true...

Pandora today announced preliminary and unaudited results for 2025. The company is expected to deliver organic growth of 6% for 2025, marginally below the prior guidance of 7-8%. Group EBIT margin for 2025 is expected to be in line with guidance of around 24%. Pandora will, as already communicated, announce audited full-year 2025 results on 5 February, 2026. The top-line performance reflects a year marked by a generally weak consumer sentiment, with North America being particularly impacted in Q4 2025.  The bottom-line performance demonstrates strong gross margins and cost discipline which partially offset significant external headwinds from commodity prices, foreign exchange rates, and tariffs. Berta de Pablos-Barbier was appointed as President & CEO of Pandora on 1 January, 2026. On 5 February, alongside the full-year results, she...